Skip to main content
Hugel, Inc. logo

Hugel, Inc. — Investor Relations & Filings

Ticker · 145020 ISIN · KR7145020004 KO Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2023-05-10 Regulatory Filings
Country KR South Korea
Listing KO 145020

About Hugel, Inc.

https://www.hugel-inc.com/

Hugel, Inc. is a global biopharmaceutical company specializing in the medical aesthetics and therapeutics market. The company develops, manufactures, and distributes a portfolio of high-quality products, including its flagship botulinum toxin type A formulations, known commercially as Botulax and Letybo. Its product line also features a range of hyaluronic acid (HA) fillers and PDO threads. Recognized as a leader in its field, Hugel is focused on providing innovative, efficient, and proven solutions to medical professionals worldwide. The company is committed to advancing aesthetic medicine through continuous research and development to create effective and reliable treatments.

Recent filings

Filing Released Lang Actions
풍문또는보도에대한해명(미확정)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding a 'Clarification of Rumors or Reports' (풍문 또는 보도에 대한 해명). It addresses media speculation about a potential delisting or strategic changes involving the company's major shareholder. Since this is a standard regulatory disclosure regarding market rumors that does not fit into specific categories like M&A or share issues, it falls under the general regulatory filing category.
2023-05-10 Korean
투자판단관련주요경영사항(임상시험계획자진취하등)(비대흉터 치료제(BMT101)의 임상 2a상 시험 조기종료 결정)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically details the early termination of a clinical trial (BMT101) due to a change in business strategy and the termination of a technology transfer agreement. Since this is a specific regulatory disclosure regarding clinical trial status and business strategy changes that does not fit into categories like M&A, Earnings, or Dividends, it is classified as a Regulatory Filing (RNS).
2023-05-10 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. It is not the presentation itself, but rather a notification of the event and the scheduled availability of materials. According to the 'Menu vs Meal' rule, announcements of events or report publications are classified as Regulatory Filings (RNS) when they do not fit other specific categories like RPA.
2023-05-10 Korean
결산실적공시예고
Report Publication Announcement Classification · 100% confidence The document is a short notice (493 characters) titled '결산실적공시 예고' (Notice of Earnings Release). It informs shareholders of the upcoming date (2023-05-10) for the release of the Q1 2023 financial results. Per the 'Menu vs Meal' rule, since this is an announcement regarding the timing of a future report rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2023-05-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (a conference call for Q1 2023 results). It provides the date, time, and purpose of the meeting but is not the presentation itself or the full financial report. According to the 'Menu vs Meal' rule, an announcement of an event or report publication is classified as a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2023-05-03 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Trust Contract Termination Report' (신탁계약해지결과보고서) filed by Hugel Co., Ltd. with the Financial Supervisory Service (FSS) in South Korea. It details the termination of a stock repurchase trust contract and the subsequent status of treasury shares. This type of filing, which reports on the company's own share transactions and trust contract status, falls under the category of 'Transaction in Own Shares' (POS).
2023-04-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.